Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC2A1 | P11166 | 4/20 | 0.64 |
| ▸ | MAPK8 | P45983 | 2/20 | 0.64 |
| ▸ | MAPK9 | P45984 | 2/20 | 0.64 |
| ▸ | KDR | P35968 | 3/20 | 0.63 |
| ▸ | AURKA | O14965 | 1/20 | 0.63 |
| ▸ | AURKB | Q96GD4 | 1/20 | 0.63 |
| ▸ | CDK19 | Q9BWU1 | 1/20 | 0.63 |
| ▸ | MAPK10 | P53779 | 1/20 | 0.62 |
| ▸ | IGF1R | P08069 | 1/20 | 0.56 |
| ▸ | ABL1 | P00519 | 5/20 | 0.55 |
| ▸ | BCR | P11274 | 5/20 | 0.55 |
| ▸ | PDGFRB | P09619 | 3/20 | 0.55 |
| ▸ | PDGFRA | P16234 | 3/20 | 0.55 |
| ▸ | SRC | P12931 | 3/20 | 0.55 |
| ▸ | PRKCA | P17252 | 3/20 | 0.55 |
| ▸ | PRKCD | Q05655 | 3/20 | 0.55 |
| ▸ | PRKD3 | O94806 | 1/20 | 0.55 |
| ▸ | PRKCG | P05129 | 1/20 | 0.55 |
| ▸ | PRKCB | P05771 | 1/20 | 0.55 |
| ▸ | PRKCH | P24723 | 1/20 | 0.55 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3443704 | 0.97 | SLC2A1 (0.66) | SLC2A1MAPK8MAPK9KDRAURKA | |
| SCHEMBL3441707 | 0.96 | SLC2A1 (0.64) | SLC2A1MAPK8MAPK9KDRAURKA | |
| SCHEMBL3446536 | 0.95 | SLC2A1 (0.64) | SLC2A1MAPK8MAPK9KDRAURKA | |
| SCHEMBL3442447 | 0.94 | SLC2A1 (0.61) | SLC2A1MAPK8MAPK9KDRAURKA | |
| SCHEMBL3442220 | 0.93 | SLC2A1 (0.62) | SLC2A1MAPK8MAPK9KDRAURKA | |
| SCHEMBL3441842 | 0.92 | SLC2A1 (0.61) | SLC2A1MAPK8MAPK9KDRAURKA | |
| SCHEMBL3441968 | 0.91 | SLC2A1 (0.63) | SLC2A1MAPK8MAPK9KDRAURKA | |
| SCHEMBL3442268 | 0.91 | SLC2A1 (0.76) | SLC2A1MAPK8MAPK9KDRAURKA | |
| SCHEMBL3442067 | 0.91 | SLC2A1 (0.60) | SLC2A1MAPK8MAPK9KDRAURKA | |
| SCHEMBL3443396 | 0.91 | SLC2A1 (0.67) | SLC2A1MAPK8MAPK9KDRAURKA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7812022-B2 | 2-pyrimidinyl pyrazolopyridine ErbB kinase inhibitors | GLAXOSMITHKLINE LLC (US) | 2010-10-12 | — | — | US | disclosed |
| US-7812022-B2 | 2-pyrimidinyl pyrazolopyridine ErbB kinase inhibitors | GLAXOSMITHKLINE LLC (US) | 2010-10-12 | — | — | US | disclosed |
| EP-1828185-B1 | 2-PYRIMIDINYL PYRAZOLOPYRIDINE ERBB KINASE INHIBITORS | SMITHKLINE BEECHAM CORP (US) | 2009-05-06 | — | — | EP | disclosed |
| US-20080051395-A1 | 2-Pyrimidinyl Pyrazolopyridine Erbb Kinase Inhibitors | SMITHKLINE BEECHAM CORPORATION | 2008-02-28 | — | — | US | disclosed |
| US-20080051395-A1 | 2-Pyrimidinyl Pyrazolopyridine Erbb Kinase Inhibitors | SMITHKLINE BEECHAM CORPORATION | 2008-02-28 | — | — | US | disclosed |
| EP-1828185-A2 | 2-PYRIMIDINYL PYRAZOLOPYRIDINE ERBB KINASE INHIBITORS | SmithKline Beecham Corporation (US) | 2007-09-05 | — | — | EP | disclosed |
| WO-2006068826-A2 | 2-PYRIMIDINYL PYRAZOLOPYRIDINE ERBB KINASE INHIBITORS | SMITHKLINE BEECHAM CORPORATION (US) | 2006-06-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080051395-A1 | 2-Pyrimidinyl Pyrazolopyridine Erbb Kinase Inhibitors | ERBB2, ERBB3, ERBB4 | SLC2A1 3810/4885MAPK8 263/4885MAPK9 203/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.